(Q43113859)

14 November 2017

Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug (English)

1 reference

14 November 2017

Leishmania braziliensis

1 reference

1 reference

Francisco Gamarro

4

0 references

author name string

María P Sánchez-Cañete

1

1 reference

14 November 2017

Luís Carvalho

2

1 reference

14 November 2017

F Javier Pérez-Victoria

3

1 reference

14 November 2017

Santiago Castanys

5

1 reference

14 November 2017

language of work or name

English

0 references

publication date

2 February 2009

1 reference

Antimicrobial Agents and Chemotherapy

14 November 2017

1 reference

14 November 2017

53

1 reference

14 November 2017

4

1 reference

14 November 2017

1305-1313

1 reference

Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

14 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

Cutaneous leishmaniasis treatment

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

Treatment of New World cutaneous leishmaniasis with miltefosine

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

Oral miltefosine for the treatment of Indian visceral leishmaniasis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

Characterization of an HL-60 cell variant resistant to the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

Automated laser-induced fluorescence DNA sequencing: equalizing signal-to-noise ratios significantly enhances overall performance

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L).

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

Animal cell mutants unable to take up biologically active glycerophospholipids.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

Miltefosine for new world cutaneous leishmaniasis.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

Rapid transport of phospholipids across the plasma membrane of Leishmania infantum

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2663093

In vitro activity of perifosine: a novel alkylphospholipid against the promastigote stage of Leishmania species

15 August 2018

1 reference

12 December 2020

Treatment of Bolivian mucosal leishmaniasis with miltefosine

1 reference

12 December 2020

Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis

1 reference

12 December 2020

Short-course of oral miltefosine for treatment of visceral leishmaniasis

1 reference

12 December 2020

Use of the green fluorescent protein as a marker in transfected Leishmania

1 reference

12 December 2020

Identifiers

DOI

10.1128/AAC.01694-08

1 reference

14 November 2017

1 reference

14 November 2017

PubMed publication ID

19188379

1 reference